BRCA Genes in Breast Cancer Chemoprevention

BRCA 基因在乳腺癌化学预防中的作用

• 批准号: 7416594
• 负责人: Eliot M. Rosen
• 金额: $ 28.61万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-04-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7416594
• 关键词: Animal Model; Antioxidants; BRCA1 Mutation; BRCA1 gene; BRCA2 gene; Biological Assay; Breast; Breast Cancer Prevention; Cancer-Predisposing Gene; Carcinogen Metabolism; Carcinogens; Categories; Cell Line; Cells; Cervical; Chemoprevention; Chemopreventive Agent; Clinical; DNA Damage; DNA Microarray Chip; DNA Microarray format; Data; Dietary Supplementation; Endometrial Carcinoma; Epithelial Cells; Estrogens; Exons; Experimental Animal Model; Experimental Models; Figs - dietary; Gene Expression; Gene Expression Profiling; Genes; Genetic Transcription; Glutathione; Goals; Growth; Hereditary Breast Carcinoma; Hormones; Human; In Vitro; Indole-3-Carbinol; Malignant neoplasm of cervix uteri; Malignant neoplasm of prostate; Mammary Tumorigenesis; Mammary gland; Mediating; Messenger RNA; Metabolism; Modeling; Molecular; Molecular Target; Mus; Mutation; Outcome Study; Pathway interactions; Pattern; Phytochemical; Prevention; Prostate; Proteins; Publishing; Risk; Role; Small Interfering RNA; Tamoxifen; Testing; Toxic effect; Transcriptional Activation; Tumor Suppressor Proteins; Up-Regulation; Woman; cancer type; cell growth; cruciferous vegetable; falls; in vivo; malignant breast neoplasm; mouse model; prevent; repaired; response; sulfotransferase; transcription factor; tumor; tumorigenesis

DESCRIPTION (provided by applicant): Background. Clinical-epidemiological and animal model studies suggest that indole-3-carbinol [I3C, a phytochemical from cruciferous vegetables] has chemopreventive activity for hormone-dependent tumor types, including breast, cervical, and endometrial cancers. Its anti-tumor activity is probably due to both hormone-dependent and hormone independent actions. Mutations of the breast cancer susceptibility genes BRCA1 and BRCA2 each confer a significantly increased risk of several hormonally-responsive cancer types (e.g., breast and prostate cancers). Preliminary studies. Our published and preliminary studies suggest that some of the hormone-dependent and hormone-independent actions of DC in human breast, cervical cancer, and prostate cell lines are mediated through the up-regulation of BRCA1 and BRCA2 expression. Gene expression profiling using DNA microarrays suggest an overlap between the gene expression patterns induced by DM (the major active metabolite of ISC) vs BRCA1. Hypothesis. We postulate that chemoprevention by I3C is due, in part, to BRCA1 (and probably BRCA2) mediated activities: e.g., inhibition of E2-stimulated cell growth and up-regulation of growth arrest and DNA damage-responsive genes (GADDs) and GSTs. I3C may also induce these and other tumor suppressor pathways independently of BRCA1; and BRCA1/2 may function synergistically with these other I3C pathways to suppress tumorigenesis. Objectives. To test these hypotheses, we will carry out three specific aims. In SA1, we will investigate the mechanism by which I3C induces BRCA1 and BRCA2; and we will assess the contribution of the endogenous BRCA genes to the estrogen-dependent and estrogen-independent molecular and cellular actions of I3C in human mammary epithelial cells, using small interfering RNAs to each BRCA gene that we have already developed. In SA2, we will assess the roles of the BRCA genes in the spectrum of DBVI-induced transcriptional alterations in mammary epithelial cells. And in SA3, we will validate some of these in vitro observations using two in vivo experimental models for prevention of mammary cancer by dietary supplementation with I3C. One model will feature a mammary-targeted mutation of Brcal. Significance. These studies will establish that the BRCA genes are molecular targets for indole-3-carbinol that contribute to its ability to prevent breast cancer. A successful outcome of these studies would suggest the use of I3C in chemoprevention of sporadic and hereditary breast cancers. The latter may be particularly useful, since recent studies suggest that Tamoxifen may not protect women with BRCA1 mutations from developing breast cancer.

描述（由申请人提供）：背景。临床流行病学和动物模型研究表明，吲哚-3-甲醇[I3 C，一种来自十字花科蔬菜的植物化学物质]对乳腺癌、子宫颈癌和子宫内膜癌等乳腺癌依赖性肿瘤类型具有化学预防活性。其抗肿瘤活性可能是由于激素依赖性和激素非依赖性作用。乳腺癌易感基因BRCA 1和BRCA 2的突变各自赋予几种对乳腺癌有反应的癌症类型（例如，乳腺癌和前列腺癌）。初步研究。我们已发表的和初步的研究表明，在人乳腺癌，宫颈癌和前列腺癌细胞系中，DC的一些依赖于乳腺癌和非依赖于乳腺癌的作用是通过上调BRCA 1和BRCA 2的表达来介导的。使用DNA微阵列的基因表达谱表明DM（ISC的主要活性代谢产物）与BRCA 1诱导的基因表达模式之间存在重叠。假说.我们假设I3 C的化学预防部分是由于BRCA 1（可能还有BRCA 2）介导的活性：例如，抑制E2刺激的细胞生长和上调生长停滞和DNA损伤应答基因（GADD）和GST。I3 C也可以独立于BRCA 1诱导这些和其他肿瘤抑制途径; BRCA 1/2可以与这些其他I3 C途径协同作用以抑制肿瘤发生。目标.为了验证这些假设，我们将实现三个具体目标。在SA 1中，我们将研究I3 C诱导BRCA 1和BRCA 2的机制;我们将评估内源性BRCA基因对I3 C在人乳腺上皮细胞中的雌激素依赖性和雌激素非依赖性分子和细胞作用的贡献，使用我们已经开发的每个BRCA基因的小干扰RNA。在SA 2中，我们将评估BRCA基因在DBVI诱导的乳腺上皮细胞转录改变谱中的作用。在SA 3中，我们将使用两种通过膳食补充I3 C预防乳腺癌的体内实验模型来验证其中一些体外观察结果。一个模型将以乳腺靶向突变的Brcal为特征。意义这些研究将确定BRCA基因是吲哚-3-甲醇的分子靶点，有助于其预防乳腺癌的能力。这些研究的成功结果表明I3 C在散发性和遗传性乳腺癌的化学预防中的应用。后者可能特别有用，因为最近的研究表明，他莫昔芬可能不能保护BRCA 1突变的女性患乳腺癌。